Karachi: Ferozsons Laboratories Limited has announced a strategic move towards acquiring Barrett Hodgson Pakistan Pvt. Limited, a development that was discussed in an emergent board meeting held on May 17, 2025. This potential acquisition is to be conducted in collaboration with a consortium of prominent business groups within Pakistan.

The decision to explore this acquisition was made after the Board of Directors reviewed a proposal put forward by the company’s Investment Committee. The board has given the green light for the Chief Executive Officer and the Chief Financial Officer to carry out due diligence as well as to appoint necessary advisors. They have also been authorized to sign requisite documents and manage other related actions such as providing bid money and security.

As per company officials, the final purchase price and equity investment required for this acquisition will be contingent upon the results of the due diligence process. The Board of Directors will make a decision based on these findings, as well as other pertinent parameters and necessary approvals.

According to information available from the Pakistan Stock Exchange (PSX), this development is part of Ferozsons Laboratories Limited's strategic initiatives within the designated market category. The pharmaceutical company seeks to expand its footprint in the industry through this acquisition, aligning with its long-term growth objectives.